U.S. Markets open in 7 hrs 55 mins
  • S&P Futures

    4,371.75
    -40.00 (-0.91%)
     
  • Dow Futures

    34,819.00
    -155.00 (-0.44%)
     
  • Nasdaq Futures

    14,816.50
    -221.25 (-1.47%)
     
  • Russell 2000 Futures

    2,216.30
    -21.20 (-0.95%)
     
  • Crude Oil

    73.09
    -0.53 (-0.72%)
     
  • Gold

    1,830.90
    -4.90 (-0.27%)
     
  • Silver

    25.59
    -0.19 (-0.73%)
     
  • EUR/USD

    1.1881
    -0.0016 (-0.1307%)
     
  • 10-Yr Bond

    1.2690
    0.0000 (0.00%)
     
  • Vix

    17.70
    -0.61 (-3.33%)
     
  • GBP/USD

    1.3940
    -0.0018 (-0.1310%)
     
  • USD/JPY

    109.5300
    +0.0690 (+0.0630%)
     
  • BTC-USD

    39,731.77
    -192.23 (-0.48%)
     
  • CMC Crypto 200

    945.59
    +15.23 (+1.64%)
     
  • FTSE 100

    7,078.42
    +61.79 (+0.88%)
     
  • Nikkei 225

    27,293.88
    -488.54 (-1.76%)
     

UPDATE 2-EMA starts review of GSK's monoclonal antibody to treat COVID-19 patients

·2 min read

(Adds GSK-Vir statement)

April 15 (Reuters) - The European Medicines Agency said on Thursday it is reviewing available data on the use of GlaxoSmithKline's monoclonal antibody to treat COVID-19 patients.

The agency said its review of VIR-7831, which GSK is developing with Vir Biotechnology Inc, will include data from a study comparing its effect with that of a placebo in patients with mild to moderate COVID-19 who were at high risk of progressing to a more severe condition. (https://bit.ly/3n0spGx)

While a more comprehensive rolling review is expected to start at a later time, the agency said the current review will provide European Union-wide recommendations for national authorities who may take decisions on early use of the medicine.

The companies reported in March that VIR-7831 reduced the risk of hospitalisation and deaths among patients by 85%, based on interim data from a study.

VIR-7831 has not been granted a marketing authorisation anywhere in the world. The companies said in a statement on Thursday they planned to submit a full marketing authorisation application to the EMA, and talks with global regulators were on to make VIR-7831 available to patients with COVID-19.

In late March, the companies filed an application to U.S. regulators for emergency use authorization of VIR-7831 to treat early-stage COVID-19 infections.

The United States has already recommended similar therapies from Eli Lilly and Co and Regeneron Pharmaceuticals Inc .

European health regulators are reviewing treatments from this class of medicines called monoclonal antibodies, which are synthetically manufactured copies of the human body's natural infection-fighting proteins and are already being used to treat some types of cancers.

GSK and Vir announced a partnership in 2020 to research COVID-19 treatments, and earlier this year said they will expand that partnership to develop monoclonal antibody treatments for influenza and other respiratory illnesses. (Reporting by Vishwadha Chander in Bengaluru; Editing by Bernard Orr and David Evans)